On March 7, 2025, Conduit Pharmaceuticals applied to Nasdaq and is compliant with the listing standard of having a market value over $1 million; as of March 31, 2025, they reported stockholder's equity of $2.8 million, meeting the $2.5 million requirement despite expected losses.